围手术期抗生素预防结直肠ESD后凝血综合征的多中心随机对照试验
本研究为日本21家三级机构开展的前瞻性多中心随机对照优效性试验,纳入 superficial 结直肠病变≥20 mm行ESD患者432例,随机分为抗生素组(氨苄西林-舒巴坦3 g术前、术后8小时及次日晨给药)与非抗生素组。
要点
- 结直肠ESD围手术期使用氨苄西林-舒巴坦未显著降低PECS发生率。
- PECS发生率抗生素组4.7% vs 非抗生素组7.5%,差异无统计学意义。
- 研究因无效而得出阴性结论,不支持常规预防性使用抗生素。
核心结论
- 围手术期使用抗生素不能有效降低结直肠ESD患者PECS的发生率。
研究设计与样本
- 前瞻性、多中心、随机对照、平行、优效性试验,在日本21家三级机构开展。
- 纳入 superficial 结直肠病变≥20 mm且行单病灶ESD的患者,共432例随机分组(抗生素组216例,非抗生素组216例),排除ESD术中及术后穿孔者。
- 最终分析抗生素组192例、非抗生素组188例。
主要发现
- PECS发生率抗生素组为4.7%(9/192),非抗生素组为7.5%(14/188)。
关键数值与推荐
- 抗生素方案:氨苄西林-舒巴坦3 g于ESD术前、术后8小时及次日晨各给药一次。
临床怎么用
- 结直肠ESD围手术期不推荐常规预防性使用抗生素以预防PECS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: This study aimed to evaluate the efficacy of perioperative antibiotics against post-endoscopic submucosal dissection (ESD) coagulation syndrome (PECS) in patients undergoing colorectal ESD. METHODS: A prospective, multicenter, randomized controlled, parallel, superiority trial was conducted at 21 Japanese tertiary institutions. Patients with superficial colorectal lesions ≥20 mm and those undergoing ESD management for a single lesion were eligible. Patients with perforation during and after ESD were withdrawn. Before the ESD procedure, participants were randomly assigned (1:1) to either undergo conventional treatment (nonantibiotic group) or investigational treatment (antibiotic group). In the antibiotic group, 3 g of ampicillin-sulbactam was administered just before, 8 hours after, and the morning after ESD. The primary endpoint was the incidence of PECS. The onset of PECS was defined as localized abdominal pain (both spontaneous pain and tenderness) and fever (≥37.6°C) or inflammatory response (leukocytosis [≥10,000 cells/μL] or elevated C-reactive protein level [≥.5 mg/dL]). RESULTS: From February 5, 2019 to September 7, 2020, 432 patients were enrolled and assigned to the antibiotic group (n = 216) or nonantibiotic group (n = 216). After withdrawal of 52 patients, 192 in the antibiotic group and 188 in the nonantibiotic group were analyzed. PECS occurred in 9 of 192 patients (4.7%) in the antibiotic group and 14 of 188 patients (7.5%) in the nonantibiotic group, with an odds ratio of .61 (95% confidence interval, .23-1.56; P = .29). CONCLUSIONS: Perioperative use of antibiotics was not effective in reducing the incidence of PECS in patients undergoing colorectal ESD. (Clinical trial registration number: UMIN000035178.).
引用
- Shichijo S, Takeuchi Y, Shimodate Y, et al. Performance of perioperative antibiotics against post-endoscopic submucosal dissection coagulation syndrome: a multicenter randomized controlled trial. Gastrointest Endosc. 2021. PMID: 34499904. doi:10.1016/j.gie.2021.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。